Smith & Nephew PLC
SN.: XLON (GBR)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|>? | LOCK|#Msf | LOCK|<$&vs$ |
Smith & Nephew Earnings: Lackluster Knee Growth Offset by Hips and Sports Medicine
Smith & Nephew's third-quarter performance included year-over-year revenue growth in the orthopedics and sports medicine segments of 4% and 5%, respectively, on an underlying basis.
